Amendment to Schedule 13D Filing for Eupraxia Pharmaceuticals Inc.

This filing, Amendment No. 2 to the Schedule 13D, concerns Eupraxia Pharmaceuticals Inc. and updates information regarding beneficial ownership. Joseph S. Freedman, the Reporting Person, has acquired additional shares through various transactions in February 2026. These include purchases in an underwritten public offering, exercise of warrants by a trust, and exercise of warrants by Mr. Freedman's children. As of March 13, 2026, Mr. Freedman beneficially owns 5,843,215 shares, representing 9.0% of the class, with sole voting and dispositive power over 4,309,205 shares. The filing details the sources of funds for these acquisitions, primarily personal funds and trust funds. No transactions other than those disclosed in Item 3 have occurred in the 60 days prior to filing.